About The Study

This study is for those with scarring of the liver due to MASH (metabolic dysfunction-associated steatohepatitis), also sometimes called “fatty liver.” Participants will add a once-weekly injection of an investigational medicine or placebo to their current medications. The purpose of the study is to see if this investigational medicine is safe and effective in order to be used as a new treatment for MASH.

To take part in the study, participants should be:

• Diagnosed with MASH (or ‘Fatty Liver’)
• Willing to have a liver biopsy performed
• A1c less than 10%